Asunto(s)
Mano/cirugía , Ortopedia/historia , Sociedades Médicas , Francia , Historia del Siglo XX , Historia del Siglo XXI , HumanosRESUMEN
The childhood cancer survival rate is currently 75% in industrialized countries. Rates in developing countries are much lower. The Franco-African Childhood Cancer Group (French acronym, GFAOP) was founded in 2000 with aim of reducing this unfavorable situation in Africa. The GFAOP has developed two forms of action. The main form consists of organizing two- to twelve-month training sessions for physicians and nurses in France and Morocco. The other form involves assessing the feasibility of modern treatment protocols for various cancers in Africa. The first feasibility trials were carried out on nephroblastoma and Burkitt's lymphoma in 12 pilot units in North Africa, West Africa, and Madagascar. In the first study from 2001 to 2005 we treated 306 cases of Burkitt's lymphoma using French LMB protocols adapted to the African setting and achieved a survival rate of 61%. A second study started in 2005 using Endoxan alone achieved a highly satisfactory survival rate of 73% for neuroblastoma in all stages except bilateral. Altogether from 2001 to 2007 more than 1000 cases of nephroblastoma and Burkitt's lymphoma were treated in African hospitals by African doctors and nurses. No patients were transferred to Europe. The GFAOP supplied drugs when necessary and took care of most travel expenses. African and French doctors worked together on protocol design, trial management, and data analysis. These promising results show that the latest therapeutic techniques can be used to treat childhood cancer in Africa by adapting the protocol to conditions in developing countries. Sanofi-Aventis Laboratories in association with the International Union against Cancer has launched a major campaign to improve Pediatric Oncology in developing countries. Projects in four GFAOP units are being financed through this campaign. In 2006 the GFAOP began assessment of two new treatment protocols, i.e., one for acute lymphoblastic leukemia and the other for Hodgkin's disease. Two other projects are being planned, i.e., one for treatment of retinoblastoma and the other for treatment of some types of brain tumors.
Asunto(s)
Cooperación Internacional , Neoplasias/terapia , África , Niño , Protocolos Clínicos , Países en Desarrollo , Francia , HumanosAsunto(s)
Neoplasias/terapia , Sociedades Médicas/organización & administración , África , Niño , Francia , HumanosAsunto(s)
Linfoma de Células B/tratamiento farmacológico , Tumor de Wilms/tratamiento farmacológico , Adolescente , África , Niño , Preescolar , Femenino , Francia , Humanos , Lactante , MasculinoRESUMEN
Antibioprophylaxy in surgery follows, in France, the guidelines published by the French Society of Anesthesia [Société française d'Anesthésie et reanimation (SFAR)]. However these guidelines were mostly made for prosthetic and traumatologic surgery of the lower limb and guidelines for upper limb and hand surgery have been made by extrapolation. The French Society for Surgery of the hand has made multiples studies including: a survey to precise the infection rate for hand surgery which has been estimated to be around 0.1%. A search in the international literature, according to the classification criteria proposed by the "Agence Nationale D'accréditation et d'Evaluation Sanitaire (ANAES)" to better define correct antibioprophylaxy that should be used in hand surgery. Results of those surveys have been presented by national experts at the French Society Meeting of 2003. The attendance was given the opportunity to answer questions from the experts. A jury was present and its conclusion are reported here. Except for total wrist prosthesis and for surgical procedures that last more than 2 hours, there are very few indications for an antibioprophylaxy in hand surgery. In cases where an antibioprophylaxy is needed, the jury recommends that the guidelines proposed by the SFAR, regarding the choice of antibiotics, should be followed.
Asunto(s)
Profilaxis Antibiótica , Mano/cirugía , Guías de Práctica Clínica como Asunto , Infección de la Herida Quirúrgica/prevención & control , Francia , Encuestas Epidemiológicas , Humanos , Pautas de la Práctica en Medicina/estadística & datos numéricos , Implantación de Prótesis , Sociedades MédicasRESUMEN
Thumb reconstruction following amputation is usually performed in order to restore function. Nevertheless, the reconstruction should be cosmetically acceptable in order to be fully functional, and, in some cases, reconstructive surgery may be justified for purely aesthetic reasons. The most satisfying aesthetic results in adults are obtained with microsurgical partial great-toe transfer. The technique that we use for thumb reconstruction is illustrated by two case reports: that of a 26-year-old female patient and that of a 35-year-old male patient. Both patients had a distal thumb amputation with destroyed nail apparatus, and both sought thumb reconstruction for cosmetic reasons. Aesthetic reconstruction was performed in both cases with a partial ipsilateral great-toe transfer, composed of nail apparatus, underlying bone and custom-made pulp tissue. The vascular anastomosis was done at the snuff-box, through a small incision, with an exteriorised pedicle. The result was satisfactory in both cases, with minimal donor-site sequelae. Partial toe transfer has proven to be a reliable technique for thumb reconstruction. It is an evolving technique. Many modifications have been introduced to optimise the aesthetic result and to reduce donor-site morbidity. Our technique allows us to restore thumb length, replace the missing nail and reconstruct the pulp, with acceptable sequelae at the donor toe. The exteriorised-pedicle technique prevents pedicle compression and twisting and reduces scarring and stiffness. It does, however, require delicate postoperative care and a second procedure for pedicle division.
Asunto(s)
Amputación Traumática/cirugía , Procedimientos de Cirugía Plástica/métodos , Pulgar/lesiones , Dedos del Pie/trasplante , Adulto , Sangre , Prótesis Vascular , Implantación de Prótesis Vascular/métodos , Estética , Femenino , Humanos , Masculino , Microcirculación , Microcirugia/métodos , Cuidados Posoperatorios , Pulgar/cirugíaRESUMEN
The family history of cancer in children treated for a solid malignant tumour in the Paediatric Oncology Department at Institute Gustave-Roussy, has been investigated. In order to determine the role of germline p53 mutations in genetic predisposition to childhood cancer, germline p53 mutations were sought in individuals with at least one relative (first- or second-degree relative or first cousin) affected by any cancer before 46 years of age, or affected by multiple cancers. Screening for germline p53 mutation was possible in 268 index cases among individuals fulfilling selection criteria. Seventeen (6.3%) mutations were identified, of which 13 were inherited and four were de novo. Using maximum likelihood methods that incorporate retrospective family data and correct for ascertainment bias, the lifetime risk of cancer for mutation carriers was estimated to be 73% for males and nearly 100% for females with a high risk of breast cancer accounting for the difference. The risk of cancer associated with such mutations is very high and no evidence of low penetrance mutation was found. These mutations are frequently inherited but de novo mutations are not rare.
Asunto(s)
Genes p53 , Mutación de Línea Germinal , Heterocigoto , Neoplasias/genética , Adulto , Factores de Edad , Niño , Preescolar , Femenino , Predisposición Genética a la Enfermedad , Pruebas Genéticas , Humanos , Lactante , Masculino , Riesgo , Factores SexualesRESUMEN
PURPOSE: The French Society of Pediatric Oncology MDH82 study demonstrated the effectiveness of 20 Gy irradiation of involved fields after doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) or mechlorethamine, vincristine, procarbazine, and prednisone/ABVD chemotherapy in children with localized Hodgkin's disease (HD). The response to primary chemotherapy was the only predictor of survival. To reduce long-term treatment complications without compromising efficacy, the MDH90 study was based on a new chemotherapy regimen devoid of both alkylating agents and anthracycline, followed by 20 Gy of radiotherapy (RT) for good responders. PATIENTS AND METHODS: From January 1990 to July 1996, 202 children were enrolled from 30 institutions. Good responders to four cycles of vinblastine, bleomycin, etoposide (VP16), and prednisone (VBVP) were given 20 Gy of RT and no further therapy. Poor responders were given vincristine, procarbazine, prednisone, and doxorubicin. After a second evaluation, good responders were given 20 Gy of RT, and poor responders were given 40 Gy of RT. RESULTS: One hundred seventy-one patients (85%) were good responders to VBVP, 27 (15%) were poor responders, and four did not respond. With a median follow-up of 74 months (range, 25 to 117 months), the 5-year overall survival rate (mean +/- SD) is 97.5% +/- 2.1%, and the event-free survival rate (mean +/- SD) is 91.1% +/- 1.8%. Significant predictors of worse event-free survival in multivariate analysis were hemoglobin < 10.5 g/L, "b" biologic class, and nodular sclerosis. CONCLUSION: These results suggest that most children with clinical stage I and II HD can be treated with chemotherapy devoid of alkylating agents and anthracycline, followed by low-dose RT.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Enfermedad de Hodgkin/tratamiento farmacológico , Enfermedad de Hodgkin/radioterapia , Adolescente , Bleomicina/administración & dosificación , Niño , Preescolar , Terapia Combinada , Dacarbazina/administración & dosificación , Supervivencia sin Enfermedad , Doxorrubicina/administración & dosificación , Etopósido/administración & dosificación , Femenino , Enfermedad de Hodgkin/patología , Humanos , Masculino , Prednisona/administración & dosificación , Dosificación Radioterapéutica , Resultado del Tratamiento , Vinblastina/administración & dosificaciónRESUMEN
BACKGROUND: The thyroid gland is among the most radiosensitive organs. However, little is known about the long-term risk of developing a thyroid tumor after fractionated external radiotherapy for cancer during childhood. OBJECTIVE: To study the long-term risk of developing a thyroid tumor in 4096 three-year survivors of childhood cancer treated between May 1942 and December 1985 in 8 centers in France and the United Kingdom, 2827 of whom had received external radiotherapy. METHODS: A wide range of radiation doses were given to the thyroid: 1164 children received less than 0.5 Gy and 812 received more than 5.0 Gy, the average dose being 7.0 Gy. RESULTS: After mean follow-up of 15 years (range, 3-45 years), 14 patients-all of whom had received radiotherapy-developed a clinical thyroid carcinoma. Within the cohort, the relation between radiation dose to the thyroid and risk of thyroid carcinoma and adenoma was similar to that observed in patients who received radiotherapy during childhood for other reasons, such as an excess relative risk per gray of 4 to 8, up to a few gray. In contrast, compared with thyroid cancer incidence in the general population, the standardized incidence of thyroid carcinoma was much higher than expected from the dose-response relationship estimated within the cohort and from patients who received radiotherapy during childhood for other reasons: a dose of 0.5 Gy was associated with a standardized incidence ratio of 35 (90% confidence interval, 10-87) and a dose of 3.6 Gy with a standardized incidence ratio of 73 (90% confidence interval, 28-153). We did not show a reduction in excess relative risk per gray with use of an increasing number of fractions. CONCLUSION: Although we cannot estimate the exact proportion, it is probable that some or all children who are treated for cancer are predisposed to developing a thyroid carcinoma.
Asunto(s)
Neoplasias Inducidas por Radiación/epidemiología , Neoplasias Primarias Secundarias/epidemiología , Neoplasias de la Tiroides/etiología , Adenoma/epidemiología , Adenoma/etiología , Adolescente , Adulto , Carcinoma/epidemiología , Carcinoma/etiología , Niño , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Francia/epidemiología , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Dosificación Radioterapéutica , Estudios Retrospectivos , Factores de Riesgo , Neoplasias de la Tiroides/epidemiología , Factores de Tiempo , Reino Unido/epidemiologíaRESUMEN
Nosocomial infections are an important cause of morbidity and mortality. Methicillin resistant Staphylococcus aureus (MRSA) is often the severe causal agent in this kind of infections. In order to evaluate risk factors for nosocomial infections and nasal MRSA carriage, an incidence study was carried out on patients hospitalized in an orthopaedic surgery department in Boucicaut Hospital (Paris). This study was carried out over a five month period. Data of all the patients who stayed more than two days in the unit were collected in medical and nursing records. Nasal swab specimens were taken at the admission of each patient included in order to screen nasal MRSA carriers. Statistical analysis were performed using Epi Info software version 6.0. A total of 451 patients were included in the study. Nosocomial infections incidence rate was 11.5%. Risk factor significantly associated with nosocomial infection was high wound containation classes III and IV (Altemeier). Incidence rate of MRSA carriage was 3.1%. A previous hospitalization in a general hospital 6 months before an admission at Boucicaut Hospital was the only risk factor identified. According to this, these patients, when they are admitted, are proposed to be preventely isolated awaiting their microbiological results.
Asunto(s)
Infección Hospitalaria/epidemiología , Resistencia a la Meticilina , Ortopedia , Infecciones Estafilocócicas/epidemiología , Staphylococcus aureus/clasificación , Infección Hospitalaria/microbiología , Infección Hospitalaria/transmisión , Femenino , Registros de Hospitales , Unidades Hospitalarias , Humanos , Incidencia , Tiempo de Internación , Masculino , Persona de Mediana Edad , Registros de Enfermería , Procedimientos Ortopédicos , Paris/epidemiología , Estudios Retrospectivos , Infecciones Estafilocócicas/microbiología , Infecciones Estafilocócicas/transmisión , Staphylococcus aureus/efectos de los fármacos , Staphylococcus aureus/aislamiento & purificación , Infección de la Herida Quirúrgica/epidemiología , Infección de la Herida Quirúrgica/microbiología , Infección de la Herida Quirúrgica/transmisiónAsunto(s)
Neoplasias/terapia , Adolescente , Adulto , Niño , Humanos , Neoplasias/tratamiento farmacológico , Neoplasias/radioterapia , Neoplasias/cirugíaRESUMEN
The variation in the risk of solid second malignant neoplasms (SMN) with time since first cancer during childhood has been previously reported. However, no study has been performed that controls for the distribution of radiation dose and the aggressiveness of past chemotherapy, which could be responsible for the observed temporal variation of the risk. The purpose of this study was to investigate the influence of the treatment on the long-term pattern of the incidence of solid SMN after a first cancer in childhood. We studied a cohort of 4400 patients from eight centres in France and the UK. Patients had to be alive 3 years or more after a first cancer treated before the age of 17 years and before the end of 1985. For each patient in the cohort, the complete clinical, chemotherapy and radiotherapy history was recorded. For each patient who had received external radiotherapy, the dose of radiation received by 151 sites of the body were estimated. After a mean follow-up of 15 years, 113 children developed a solid SMN, compared to 12.3 expected from general population rates. A similar distribution pattern was observed among the 1045 patients treated with radiotherapy alone and the 2064 patients treated with radiotherapy plus chemotherapy; the relative risk, but not the excess absolute risk, of solid SMN decreased with time after first treatment; the excess absolute risk increased during a period of at least 30 years after the first cancer. This pattern remained after controlling for chemotherapy and for the average dose of radiation to the major sites of SMN. It also remained when excluding patients with a first cancer type or an associated syndrome known to predispose to SMN. When compared with radiotherapy alone, the addition of chemotherapy increases the risk of solid SMN after a first cancer in childhood, but does not significantly modify the variation of this risk during the time after the first cancer.
Asunto(s)
Neoplasias Primarias Secundarias/terapia , Edad de Inicio , Antineoplásicos/uso terapéutico , Niño , Preescolar , Relación Dosis-Respuesta en la Radiación , Estudios de Seguimiento , Francia/epidemiología , Humanos , Incidencia , Lactante , Neoplasias Primarias Secundarias/epidemiología , Factores de Riesgo , Factores de Tiempo , Reino Unido/epidemiologíaRESUMEN
Administration of combination chemotherapy to children with metastatic neuroblastoma induces profound myelosuppression resulting in chemotherapy treatment delays and febrile neutropenic episodes. The objective of this randomised multicentre study was to assess the incidence, duration and severity of neutropenia when filgrastim is added to induction chemotherapy administered to patients with metastatic neuroblastoma. In this study, 59 patients with metastatic neuroblastoma were randomised to receive chemotherapy (control group, n = 28) or chemotherapy plus filgrastim (filgrastim group, n = 31). Chemotherapy consisted of four cycles of cyclophosphamide, vincristine and doxorubicin (CADO) alternating at 21-day intervals with cisplatin and etoposide (CDDP-VP16). Filgrastim was administered subcutaneously at a dose of 5 micrograms/kg/day from day 7 for up to 14 days. The incidence of neutropenia (absolute neutrophil count [ANC] < 0.5 x 10(9)/l) in the filgrastim group was not reduced after the first CADO course. However, significant reductions were observed after courses 2, 3 and 4. The duration of neutropenia and of intravenous antibiotic use were significantly reduced in the filgrastim group over the whole study period (9 days versus 26 days, P < 0.001; 12 days versus 20 days, P = 0.04, respectively). However, the duration of hospitalisation and the incidence of febrile neutropenia were not significantly reduced. Compliance to treatment was good and the ability to administer chemotherapy without treatment delays was significantly better in the filgrastim group (P < 0.05). Event-free survival was greater in the filgrastim than in the control group (2.4 years versus 1.3 years; P = 0.072). Filgrastim is a beneficial adjunct to combination induction chemotherapy used in the treatment of metastatic neuroblastoma.
Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Factor Estimulante de Colonias de Granulocitos/uso terapéutico , Neuroblastoma/terapia , Neutropenia/inducido químicamente , Niño , Preescolar , Cisplatino/efectos adversos , Ciclofosfamida/efectos adversos , Supervivencia sin Enfermedad , Doxorrubicina/efectos adversos , Etopósido/efectos adversos , Femenino , Fiebre/inducido químicamente , Filgrastim , Humanos , Lactante , Masculino , Neuroblastoma/secundario , Proteínas Recombinantes , Resultado del Tratamiento , Vincristina/efectos adversosRESUMEN
X-linked severe combined immunodeficiency (SCID-Xl) is a rare human inherited disorder in which early T and natural killer (NK) lymphocyte development is blocked. The genetic disorder results from mutations in the common gammac chain that participates in several cytokine receptors including the interleukin-2 (IL-2), IL-4, IL-7, IL-9, and IL-15 receptors. We have shown in a previous report that gammac gene transfer into SCID-Xl bone marrow (BM) cells restores efficient NK cell differentiation. In this study, we have focused on the introduction of the gammac gene into SCID-Xl hematopoietic stem cells with the goal of obtaining differentiation into mature T cells. For this purpose, we used the in vitro hybrid fetal thymic organ culture (FTOC) system in which a combination of cytokines consisting of stem cell factor (SCF), Flt-3L, IL-7, IL-1, and IL-15 is added concomitantly. In this culture system, CD34(+) marrow cells from two SCID-Xl patients were able to mature into double positive CD4(+) CD8(+) cells and to a lesser degree into CD4(+) TCRbeta+ single positive cells after retroviral-mediated gammac gene transfer. In addition, examination of the output cell population at the TCR DJbeta1 locus exhibited multiple rearrangements. These results indicate that restoration of the gammac/JAK/STAT signaling pathway during the early developmental stages of thymocytes can correct the T-cell differentiation block in SCID-Xl hematopoietic progenitor cells and therefore establishes a basis for further clinical gammac gene transfer studies.
Asunto(s)
Técnicas de Transferencia de Gen , Terapia Genética , Receptores de Antígenos de Linfocitos T gamma-delta/genética , Inmunodeficiencia Combinada Grave/genética , Linfocitos T/fisiología , Animales , Diferenciación Celular/genética , Diferenciación Celular/inmunología , Línea Celular , Humanos , Interleucina-1/farmacología , Interleucina-15/farmacología , Interleucina-7/farmacología , Ratones , Técnicas de Cultivo de Órganos , Inmunodeficiencia Combinada Grave/inmunología , Inmunodeficiencia Combinada Grave/terapia , Factor de Células Madre/farmacología , Linfocitos T/citologíaRESUMEN
Cancer incidence is low in children. Childhood tumors are different from cancers seen in adults: their growth is rapid, but they respond well to radiotherapy and chemotherapy. In the case of Wilms Tumor, Actinomycin D, Vincristine and Doxorubicin were first used with success. Ifosfamide, Etoposide and Carboplatin are now also used in selected cases. But efficient treatments have important drawbacks: growth defects in the case of radiotherapy, late cardiac toxicity due to Doxorubicin, leukemias as second tumors following Etoposide. Treatment strategy is based on prognostic factors in Wilms' tumor, and the risk/benefit ratio assessment for each group of patients, considering survival probability and the risk of late effects. Large randomised studies in the USA and in Europe resulted in cure rates over 90%, with very few expected sequelae. Preoperative chemotherapy is now successfully applied to other tumors in children.
Asunto(s)
Antineoplásicos/uso terapéutico , Neoplasias Renales/tratamiento farmacológico , Modelos Biológicos , Tumor de Wilms/tratamiento farmacológico , Preescolar , Francia/epidemiología , Humanos , Incidencia , Lactante , Neoplasias Renales/epidemiología , Tumor de Wilms/epidemiologíaRESUMEN
Osteosarcoma is the most frequent second primary cancer occurring during the first 20 years following treatment for a solid cancer in childhood. Using a cohort study of children treated for a solid cancer, we investigated the incidence and etiology of osteosarcoma as a second malignant neoplasm after childhood cancer in a cohort and a case-control study. We analysed the relationship between the local dose of radiation and the risk of osteosarcoma, taking into account chemotherapy received. A cohort study of 4,400 3-year survivors of a first solid cancer during childhood diagnosed in France or the United Kingdom, between 1942 and 1986, revealed 32 subsequent osteosarcomas. In a nested case-control study, we matched 32 cases and 160 controls for sex, type of first cancer, age at first cancer and the duration of follow-up. Parameters studied were the incidence of osteosarcoma, the cumulative local dose of irradiation and the cumulative dose of chemotherapy received by cases and controls. The risk of a osteosarcoma was found to be a linear function of the local dose of radiation (excess relative risk per gray=1.8), and was found to increase with the number of moles of electrophilic agents per square meter but not with other drugs. No interaction was noted between radiotherapy and chemotherapy. Bilateral retinoblastoma, Ewing's sarcoma and soft tissue sarcoma were found to render patients susceptible to a higher risk of developing an osteosarcoma as a second malignant neoplasm. We recommend long-term surveillance of patients who were treated during childhood for bilateral retinoblastoma, Ewing's sarcoma, soft tissue sarcoma, as well as other first cancer treated with radiotherapy plus high doses of chemotherapy, without focusing exclusively on the radiation field.
Asunto(s)
Antineoplásicos/efectos adversos , Neoplasias Óseas/epidemiología , Neoplasias Inducidas por Radiación/epidemiología , Neoplasias Primarias Secundarias/epidemiología , Neoplasias/tratamiento farmacológico , Neoplasias/radioterapia , Osteosarcoma/epidemiología , Radioterapia/efectos adversos , Adolescente , Adulto , Neoplasias Óseas/inducido químicamente , Neoplasias Óseas/etiología , Estudios de Casos y Controles , Niño , Preescolar , Estudios de Cohortes , Femenino , Estudios de Seguimiento , Francia/epidemiología , Humanos , Incidencia , Lactante , Masculino , Persona de Mediana Edad , Neoplasias Inducidas por Radiación/etiología , Neoplasias Primarias Secundarias/inducido químicamente , Neoplasias Primarias Secundarias/etiología , Oportunidad Relativa , Osteosarcoma/inducido químicamente , Osteosarcoma/etiología , Factores de Riesgo , Factores de Tiempo , Reino Unido/epidemiologíaRESUMEN
The aim of the study was to assess rates and types of nephrectomy-related complications in children nephrectomized for nephroblastoma after preoperative chemotherapy. Records of 598 Wilms' tumour patients registered in the International Society of Paediatric Oncology Trial & Study No. 9 (SIOP-9), and pretreated correctly according to the protocol with vincristine + actinomycin D +/- epirubicine or adriamycin prior to nephrectomy, were retrospectively reviewed. Forty-nine patients (8%), who suffered from 54 complications, were identified. Most frequent events were small-bowel occlusions (3.7%) and tumour ruptures (2.8%). Other complications were registered in 2.0% of cases. The low rate of nephrectomy complications and no deaths related to registered ones, are another argument for preoperative chemotherapy in Wilms' tumour patients.
Asunto(s)
Neoplasias Renales/cirugía , Nefrectomía/efectos adversos , Tumor de Wilms/cirugía , Adolescente , Antibióticos Antineoplásicos/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Quimioterapia Adyuvante , Niño , Preescolar , Dactinomicina/uso terapéutico , Europa (Continente) , Humanos , Lactante , Neoplasias Renales/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto , Estudios Retrospectivos , Vincristina/uso terapéutico , Tumor de Wilms/tratamiento farmacológicoRESUMEN
A finger stump pollicization combined with a thin wrap-around procedure from the big toe for reconstruction of the thumb is described. This technique permits excellent functional and cosmetic restoration, providing length to the new thumb as well as widening the first web. There is joint motion in the reconstructed thumb. Sensibility of the transferred pulp is good and allows fine pinch without pulp shrinkage. This method is indicated in cases of multidigit amputations, for thumb loss near the carpometacarpal joint.
Asunto(s)
Amputación Traumática/cirugía , Traumatismos de los Dedos/cirugía , Colgajos Quirúrgicos , Pulgar/lesiones , Adulto , Muñones de Amputación/cirugía , Humanos , Masculino , Pulgar/cirugía , Dedos del Pie/trasplanteRESUMEN
Dural sinus thrombosis (DST) has been reported in association with cancer in both adults and children. We describe the seven patients seen with this complication in our centre between 1981 and 1995. Diagnosis was confirmed by either cerebral CT scanning, MRI or angiography. Median age was 13 years (range 8-15). Six patients were boys. Six children were being treated for non-Hodgkin lymphoma and one for neuroblastoma. Presenting symptoms were seizures and transient neurologic deficit, often preceded by headaches. The probable cause of DST was found in two cases. Tumour localisation in the central nervous system (CNS) probably caused DST in one patient who was treated for ki 1 lymphoma. Dehydration in combination with a poor general condition seemed to be the cause of DST in the patient with neuroblastoma. In five children with stage III or IV non-Hodgkin lymphoma (three lymphoblastic lymphoma; two Burkitt's lymphoma), etiology remained unknown. In these children, DST occurred early in the course of therapy. The median interval between start of chemotherapy and onset of symptoms was 19 days (range 8-40). No child had received L-asparaginase. Prognosis was favourable, with symptoms completely disappearing without therapy within 1 to 5 days. The incidence of DST in patients with advanced stage non-Hodgkin lymphoma during induction and consolidation was calculated to be below 3%. We conclude that DST is rarely diagnosed in children with cancer. Occurrence during the initial phase of therapy for non-Hodgkin lymphoma is associated with a benign prognosis.